Pacira BioSciences, Inc. reported the first quarter ended March 31, 2026 results: revenue $177.4 million, net income $2.9 million, or $0.07 per share (basic and diluted).
“reference in such a filing. --- EX-99.1 (EX-99.1) --- FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports First Quarter 2026 Financial Results -- Total revenue of $177 million, reflecting increase of 5 percent over first quarter 2025 driven by growth across commercial portfolio, including EXPAREL volume growth of 7 percent -- -- Completed enrollment in”
Restructurings & Charges
Pacira BioSciences, Inc. announced a restructuring with charges of approximately $2.4 million to $2.8 million affecting Science Center Campus in San Diego, California (71 employees or approximately 8% of the Company’s total workforce).
“8% of the Company’s total workforce. The Company currently estimates that it will recognize pre-tax charges to its third quarter 2025 financial results of approximately $2.4 million to $2.8 million related to employee termination benefits, consisting of garden leave and severance, healthcare benefits, and, to a lesser extent, other one-time termination”
Laura Brege was appointed as Chair of the Board at Pacira BioSciences, Inc..
“the Board, upon recommendation of the Nominating, Governance and Sustainability Committee of the Board, appointed Laura Brege as Chair of the Board, effective as of immediately following the effectiveness of the Resignations.”
Andreas Wicki resigned as Member of the Board at Pacira BioSciences, Inc..
“On January 28, 2025, Paul J. Hastings, Chair of the Board of Directors (the “Board”), and Andreas Wicki, a member of the Board, each notified the Board of Pacira BioSciences, Inc. (the “Company”) of his respective decision to resign as a member of the Board, in each case, effective immediately”
Paul J. Hastings resigned as Chair of the Board at Pacira BioSciences, Inc..
“On January 28, 2025, Paul J. Hastings, Chair of the Board of Directors (the “Board”), and Andreas Wicki, a member of the Board, each notified the Board of Pacira BioSciences, Inc. (the “Company”) of his respective decision to resign as a member of the Board, in each case, effective immediately”
Daryl Gaugler was named as Executive Vice President, Commercial Operations at Pacira BioSciences, Inc..
“On January 16, 2025, Daryl Gaugler was named Executive Vice President, Commercial Operations, instead of his former title as Chief Operating Officer.”
Brendan Teehan was appointed as Chief Commercial Officer at Pacira BioSciences, Inc..
“On January 16, 2025, Brendan Teehan was appointed Chief Commercial Officer of Pacira BioSciences, Inc. (the “Company”), effective January 21, 2025.”
Lauren Riker changed role as Senior Vice President of Finance at Pacira BioSciences, Inc..
“Mr. Cross will succeed Lauren Riker, who had been serving as interim Chief Financial Officer since October 1, 2024.”
Shawn M. Cross was appointed as Chief Financial Officer at Pacira BioSciences, Inc..
“appointed Shawn M. Cross to serve as the Chief Financial Officer of the Company, effective October 21, 2024.”
Lauren Riker was appointed as interim Chief Financial Officer at Pacira BioSciences, Inc..
“On September 26, 2024, the Board of Directors of the Company (the “Board”) appointed Lauren Riker, the Company’s current Senior Vice President of Finance and principal accounting officer, to also serve as interim Chief Financial Officer of the Company (including as principal financial officer and continuing as principal accounting officer for Securities and Exchange Commission reporting purposes), effective October 1, 2024.”
Charles A. Reinhart, III departed as Chief Financial Officer at Pacira BioSciences, Inc..
“Charles A. Reinhart, III, the Company’s Chief Financial Officer, agreed that he would depart the Company effective September 30, 2024, and will continue to serve as consultant to the Company for a period of nine months thereafter.”
Gary Pace departed as Director at Pacira BioSciences, Inc..
“On June 11, 2024, Gary Pace notified the Board of Directors (the “Board”) of Pacira BioSciences, Inc. (the “Company”) of his intent to retire from the Board, effective June 30, 2024.”
Debt Financings
Pacira BioSciences, Inc. incurred convertible notes of up to an additional $37.5 million aggregate principal amount of the Notes with Jefferies LLC and J.P. Morgan Securities LLC, as representatives of the several initial purchasers at 2.125% per year maturing May 15, 2029.
“the Company granted the Initial Purchasers an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $37.5 million aggregate principal amount of the Notes on the same terms and conditions, which option was exercised in full by the Initial Purchasers on May 10, 2024.”
Material Agreements
Pacira BioSciences, Inc. entered into Indenture with Computershare Trust Company, National Association, as trustee valued at 2.125% Convertible Senior Notes due 2029 (effective 2024-05-14).
“On May 14, 2024, the Company entered into an Indenture relating to the issuance of the Notes (the “Indenture”), by and between the Company and Computershare Trust Company, National Association, as trustee (the “Trustee”).”
Material Agreements
Pacira BioSciences, Inc. entered into Purchase Agreement with Jefferies LLC and J.P. Morgan Securities LLC, as representatives of the several initial purchasers named therein valued at $250.0 million principal amount of its 2.125% Convertible Senior Notes due 2029 (effective 2024-05-09).
“On May 9, 2024, Pacira BioSciences, Inc. (the “Company”) entered into a purchase agreement (the “Purchase Agreement”) with Jefferies LLC and J.P. Morgan Securities LLC, as representatives of the several initial purchasers named therein (collectively, the “Initial Purchasers”), to issue and sell $250.0 million principal amount of its 2.125% Convertible Senior Notes due 2029”
Material Agreements
Pacira BioSciences, Inc. amended First TLA Amendment with JPMorgan Chase Bank, N.A., as administrative agent, and certain lenders (effective 2024-05-08).
“On May 8, 2024, Pacira BioSciences, Inc. (the “Company”), JPMorgan Chase Bank, N.A., as administrative agent, and certain lenders entered into a first amendment (the “First TLA Amendment”) to the Credit Agreement, dated as of March 31, 2023”
Earnings Releases
Pacira BioSciences, Inc. reported first quarter ended March 31, 2024 results: revenue $167.1 million, net income $9.0 million, EPS $0.19 per share (basic and diluted).
“First Quarter 2024 Financial Highlights • Total revenues of $167.1 million • Net product sales of $132.4 million for EXPAREL, $25.8 million for ZILRETTA, and $5.0 million for iovera° • Net income of $9.0 million, or $0.19 per share (basic and diluted)”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.